Image courtesy of Oxford Properties Group

A pair of biotech leases totaling 38,000 square feet have brought Oxford Properties Group’s 645 Summer St. property up to 100 percent occupancy.

Akouos, which develops gene therapies to treat hearing loss, signed a 10-year renewal and expansion for 75,000 square feet, doubling its occupancy in the building. Ikena Oncology leased 21,000 square feet for five years, while Monte Rosa Therapeutics signed a five-year, 17,000-square-foot lease.

In 2019, Oxford Properties partnered with Pappas Enterprises on ownership of the 42-acre business park containing nine industrial and lab buildings.

“These relationships are emblematic of our growing life sciences business, a key area of expansion for Oxford, and our ability to create a dynamic ecosystem for businesses doing important research and development,” Abby Middleton Mondani, director of leasing at Oxford, said in a statement.

CBRE’s Carolyn Wheatley, Meredith Christensen and Jeff Landers of CBRE represented Oxford in the lease transactions. Cushman & Wakefield’s Connor Barnes, Deanne Munger and Sharon Joyce represented Akouos.

Oxford, the real estate arm of the Ontario Municipal Employees Retirement System, is pursuing another life science development in Boston’s Leather District, where it’s seeking approval for a 393,500-square-foot office-lab tower at 125 Lincoln St.